In silico structure-function analysis of pathological variation in the HSD11B2 gene sequence

Physiological Genomics

Volumn 42, Issue 3, 2010, Pages 319-330

  Manning, Jonathan R ^a   Bailey, Matthew A ^a   Soares, Dinesh C ^b   Dunbar, Donald R ^a   Mullins, John J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Apparent mineralocorticoid excess; Homology modeling

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2;

APPARENT MINERALOCORTICOID EXCESS SYNDROME; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; ENZYME ACTIVITY; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HYPERTENSION; IN VIVO STUDY; MOLECULAR MECHANICS; MORTALITY; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN STRUCTURE, FUNCTION AND VARIABILITY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; AMINO ACID SEQUENCE; ANIMALS; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DNA MUTATIONAL ANALYSIS; FAMILY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; MINERALOCORTICOID EXCESS SYNDROME, APPARENT; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; POLYMORPHISM, GENETIC; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77955724819     PISSN: 10948341     EISSN: 15312267     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00053.2010     Document Type: Article

References (69)

1. Agarwal AK, Giacchetti G, Lavery G, Nikkila H, Palermo M, Ricketts M, McTernan C, Bianchi G, Manunta P, Strazzullo P, Mantero F, White PC, Stewart PM. CA-repeat polymorphism in intron 1 of HSD11B2: effects on gene expression and salt sensitivity. Hypertension 36: 187-194, 2000. (Pubitemid 30626987)
2. Alikhani-Koupaei R, Fouladkou F, Fustier P, Cenni B, Sharma AM, Deter H, Frey BM, Frey FJ. Identification of polymorphisms in the human 11beta-hydroxysteroid dehydrogenase type 2 gene promoter: functional characterization and relevance for salt sensitivity. FASEB J 21: 3618-3628, 2007.
3. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 215: 403-410, 1990. (Pubitemid 20364473)
4. +. Mol Cell Endocrinol 201: 177-187, 2003.
5. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237: 268-275, 1987.
6. Atanasov AG, Ignatova ID, Nashev LG, Dick B, Ferrari P, Frey FJ, Odermatt A. Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. J Am Soc Nephrol 18: 1262-1270, 2007.
7. Azzi A, Rehse PH, Zhu DW, Campbell RL, Labrie F, Lin SX. Crystal structure of human estrogenic 17beta-hydroxysteroid dehydrogenase complexed with 17beta-estradiol. Nat Struct Biol 3: 665-668, 1996. (Pubitemid 26260054)
8. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res 28: 235-242, 2000.
9. Brand E, Kato N, Chatelain N, Krozowski ZS, Jeunemaitre X, Corvol P, Plouin PF, Cambien F, Pascoe L, Soubrier F. Structural analysis and evaluation of the 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) gene in human essential hypertension. J Hypertens 16: 1627-1633, 1998.
10. Bray JE, Marsden BD, Oppermann U. The human short-chain dehydrogenase/reductase (SDR) superfamily: a bioinformatics summary. Chem Biol Interact 178: 99-109, 2009.
11. Brown RW, Chapman KE, Murad P, Edwards CR, Seckl JR. Purification of 11beta-hydroxysteroid dehydrogenase type 2 from human placenta utilizing a novel affinity labelling technique. Biochem J 313: 997-1005, 1996. (Pubitemid 3025559)
12. Carvajal CA, Gonzalez AA, Romero DG, Gonzalez A, Mosso LM, Lagos ET, Hevia MDP, Rosati MP, Perez-Acle TO, Gomez-Sanchez CE, Montero JA, Fardella CE. Two homozygous mutations in the 11beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endocrinol Metab 88: 2501-2507, 2003.
13. Carvajal CA, Romero DG, Mosso LM, Gonzalez AA, Campino C, Montero J, Fardella CE. Biochemical and genetic characterization of 11beta-hydroxysteroid dehydrogenase type 2 in low-renin essential hypertensives. J Hypertens 23: 71-77, 2005.
14. Coeli FB, Ferraz LFC, Lemos-Marini SHVD, Rigatto SZP, Belangero VMS, de-Mello MP. Apparent mineralocorticoid excess syndrome in a Brazilian boy caused by the homozygous missense mutation p.R186C in the HSD11B2 gene. Arq Bras Endocrinol Metabol 52: 1277-1281, 2008.
15. Cole C, Barber JD, Barton GJ. The Jpred 3 secondary structure prediction server. Nucleic Acids Res 36: W197-W201, 2008.
16. Cristobal S, Zemla A, Fischer D, Rychlewski L, Elofsson A. A study of quality measures for protein threading models. BMC Bioinformatics 2: 5, 2001.
17. Dave-Sharma S, Wilson RC, Harbison MD, Newfield R, Azar MR, Krozowski ZS, Funder JW, Shackleton CH, Bradlow HL, Wei JQ, Hertecant J, Moran A, Neiberger RE, Balfe JW, Fattah A, Daneman D, Akkurt HI, Santis CD, New MI. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 83: 2244-2254, 1998.
18. DeLano WL. The PyMOL Molecular Graphics System [online]. 2002. http://www.pymol.org.
19. Ehrensberger AH, Elling RA, Wilson DK. Structure-guided engineering of xylitol dehydrogenase cosubstrate specificity. Structure 14: 567-575, 2006.
20. Ferrari P, Obeyesekere VR, Li K, Andrews RK, Krozowski ZS. The 11beta-hydroxysteroid dehydrogenase type II enzyme: biochemical consequences of the congenital R337C mutation. Steroids 61: 197-200, 1996. (Pubitemid 26144422)
21. Ferrari P, Obeyesekere VR, Li K, Wilson RC, New MI, Funder JW, Krozowski ZS. Point mutations abolish 11beta-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess. Mol Cell Endocrinol 119: 21-24, 1996.
22. Fiser A, Sali A. ModLoop: automated modeling of loops in protein structures. Bioinformatics 19: 2500-2501, 2003. (Pubitemid 38016660)
23. Frishman D, Argos P. Knowledge-based protein secondary structure assignment. Proteins 23: 566-579, 1995.
24. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242: 583-585, 1988.
25. Gangloff A, Shi R, Nahoum V, Lin S. Pseudo-symmetry of C19 steroids, alternative binding orientations, and multispecificity in human estrogenic 17beta-hydroxysteroid dehydrogenase. FASEB J 17: 274-276, 2003.
26. Ghosh D, Sawicki M, Pletnev V, Erman M, Ohno S, Nakajin S, Duax WL. Porcine carbonyl reductase. Structural basis for a functional monomer in short chain dehydrogenases/reductases. J Biol Chem 276: 18457-18463, 2001.
27. Ghosh D, Vihkoz P. Molecular mechanisms of estrogen recognition and 17-keto reduction by human 17beta-hydroxysteroid dehydrogenase 1. Chem Biol Interact 130-132: 637-650, 2001. (Pubitemid 32295851)
28. Gomez-Sanchez EP, Ganjam V, Chen YJ, Liu Y, Clark SA, Gomez-Sanchez CE. The 11beta hydroxysteroid dehydrogenase 2 exists as an inactive dimer. Steroids 66: 845-848, 2001.
29. Henrick K, Thornton JM. PQS: a protein quaternary structure file server. Trends Biochem Sci 23: 358-361, 1998.
30. Hubbard TJP, Aken BL, Ayling S, Ballester B, Beal K, Bragin E, Brent S, Chen Y, Clapham P, Clarke L, Coates G, Fairley S, Fitzgerald S, Fernandez-Banet J, Gordon L, Graf S, Haider S, Hammond M, Holland R, Howe K, Jenkinson A, Johnson N, Kahari A, Keefe D, Keenan S, Kinsella R, Kokocinski F, Kulesha E, Lawson D, Longden I, Megy K, Meidl P, Overduin B, Parker A, Pritchard B, Rios D, Schuster M, Slater G, Smedley D, Spooner W, Spudich G, Trevanion S, Vilella A, Vogel J, White S, Wilder S, Zadissa A, Birney E, Cunningham F, Curwen V, Durbin R, Fernandez-Suarez XM, Herrero J, Kasprzyk A, Proctor G, Smith J, Searle S, Flicek P. Ensembl 2009. Nucleic Acids Res 37: D690-D697, 2009.
31. Kamide K, Kokubo Y, Hanada H, Nagura J, Yang J, Takiuchi S, Tanaka C, Banno M, Miwa Y, Yoshii M, Matayoshi T, Yasuda H, Horio T, Okayama A, Tomoike H, Kawano Y, Miyata T. Genetic variations of HSD11B2 in hypertensive patients and in the general population, six rare missense/frameshift mutations. Hypertens Res 29: 243-252, 2006.
32. Kelley LA, Sternberg MJE. Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc 4: 363-371, 2009.
33. Kitanaka S, Katsumata N, Tanae A, Hibi I, Takeyama K, Fuse H, Kato S, Tanaka T. A new compound heterozygous mutation in the 11beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endocrinol Metab 82: 4054-4058, 1997.
34. Kotelevtsev Y, Brown RW, Fleming S, Kenyon C, Edwards CR, Seckl JR, Mullins JJ. Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. J Clin Invest 103: 683-689, 1999. (Pubitemid 29122421)
35. Kristan K, Deluca D, Adamski J, Stojan J, Rizner TL. Dimerization and enzymatic activity of fungal 17beta-hydroxysteroid dehydrogenase from the short-chain dehydrogenase/reductase superfamily. BMC Biochem 6: 28, 2005.
36. Lavery GG, Ronconi V, Draper N, Rabbitt EH, Lyons V, Chapman KE, Walker EA, McTernan CL, Giacchetti G, Mantero F, Seckl JR, Edwards CRW, Connell JMC, Hewison M, Stewart PM. Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension 42: 123-129, 2003.
37. Li A, Li KX, Marui S, Krozowski ZS, Batista MC, Whorwood CB, Arnhold IJ, Shackleton CH, Mendonca BB, Stewart PM. Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. J Hypertens 15: 1397-1402, 1997. (Pubitemid 28039566)
38. Li A, Tedde R, Krozowski ZS, Pala A, Li KX, Shackleton CH, Mantero F, Palermo M, Stewart PM. Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess. Am J Hum Genet 63: 370-379, 1998.
39. Lin-Su K, Zhou P, Arora N, Betensky BP, New MI, Wilson RC. In vitro expression studies of a novel mutation delta299 in a patient affected with apparent mineralocorticoid excess. J Clin Endocrinol Metab 89: 2024-2027, 2004.
40. Lovati E, Ferrari P, Dick B, Jostarndt K, Frey BM, Frey FJ, Schorr U, Sharma AM. Molecular basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2. J Clin Endocrinol Metab 84: 3745-3749, 1999.
41. Lovell SC, Davis IW, Arendall WB, Bakker PIWD, Word JM, Prisant MG, Richardson JS, Richardson DC. Structure validation by Calpha geometry: phi, psi and Cbeta deviation. Proteins 50: 437-450, 2003.
42. Lüthy R, Bowie JU, Eisenberg D. Assessment of protein models with three-dimensional profiles. Nature 356: 83-85, 1992.
43. Mariniello B, Ronconi V, Sardu C, Pagliericcio A, Galletti F, Strazzullo P, Palermo M, Boscaro M, Stewart PM, Mantero F, Giacchetti G. Analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) in human essential hypertension. Am J Hypertens 18: 1091-1098, 2005.
44. Monder C, White PC. 11beta-Hydroxysteroid dehydrogenase. Vitam Horm 47: 187-271, 1993.
45. Mune T, Rogerson FM, Nikkilä H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11beta-hydroxysteroid dehydrogenase. Nat Genet 10: 394-399, 1995.
46. Mune T, White PC. Apparent mineralocorticoid excess: genotype is correlated with biochemical phenotype. Hypertension 27: 1193-1199, 1996. (Pubitemid 26165618)
47. Nunez BS, Rogerson FM, Mune T, Igarashi Y, Nakagawa Y, Phillipov G, Moudgil A, Travis LB, Palermo M, Shackleton C, White PC. Mutants of 11beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess. Hypertension 34: 638-642, 1999.
48. Obeid J, White PC. Tyr-179 and Lys-183 are essential for enzymatic activity of 11beta-hydroxysteroid dehydrogenase. Biochem Biophys Res Commun 188: 222-227, 1992.
49. m 11beta-hydroxysteroid dehydrogenase type II enzyme in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80: 3381-3383, 1995.
50. Obeyesekere VR, Li KX, Ferrari P, Krozowski Z. Truncation of the N- and C-terminal regions of the human 11beta-hydroxysteroid dehydrogenase type 2 enzyme and effects on solubility and bidirectional enzyme activity. Mol Cell Endocrinol 131: 173-182, 1997.
51. Odermatt A, Arnold P, Stauffer A, Frey BM, Frey FJ. The N-terminal anchor sequences of 11beta-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J Biol Chem 274: 28762-28770, 1999. (Pubitemid 129504754)
52. Odermatt A, Dick B, Arnold P, Zaehner T, Plueschke V, Deregibus MN, Repetto H, Frey BM, Frey FJ, Ferrari P. A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension. J Clin Endocrinol Metab 86: 1247-1252, 2001.
53. Persson B, Kallberg Y, Bray JE, Bruford E, Dellaporta SL, Favia AD, Duarte RG, Jörnvall H, Kavanagh KL, Kedishvili N, Kisiela M, Maser E, Mindnich R, Orchard S, Penning TM, Thornton JM, Adamski J, Oppermann U. The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative. Chem Biol Interact 178: 94-98, 2009.
54. Poch E, González D, Giner V, Bragulat E, Coca A, de La Sierra A. Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphisms. Hypertension 38: 1204-1209, 2001.
55. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234: 779-815, 1993. (Pubitemid 24007801)
56. Shen M, Sali A. Statistical potential for assessment and prediction of protein structures. Protein Sci 15: 2507-2524, 2006.
57. Smolenicka Z, Bach E, Schaer A, Liechti-Gallati S, Frey BM, Frey FJ, Ferrari P. A new polymorphic restriction site in the human 11beta-hydroxysteroid dehydrogenase type 2 gene. J Clin Endocrinol Metab 83: 1814-1817, 1998.
58. Stewart PM, Corrie JE, Shackleton CH, Edwards CR. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. J Clin Invest 82: 340-349, 1988.
59. Stewart PM, Krozowski ZS, Gupta A, Milford DV, Howie AJ, Sheppard MC, Whorwood CB. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11beta-hydroxysteroid dehydrogenase type 2 gene. Lancet 347: 88-91, 1996.
60. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25: 4876-4882, 1997. (Pubitemid 28022245)
61. Ulick S, Tedde R, Mantero F. Pathogenesis of the type 2 variant of the syndrome of apparent mineralocorticoid excess. J Clin Endocrinol Metab 70: 200-206, 1990.
62. Vriend G, Sander C. Quality control of protein models: directional atomic contact analysis. J Appl Crystallogr 26: 47-60, 1993. (Pubitemid 23611937)
63. Wallner B, Elofsson A. Can correct protein models be identified? Protein Sci 12: 1073-1086, 2003.
64. Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ. Jalview Version 2 - a multiple sequence alignment editor and analysis workbench. Bioinformatics 25: 1189-1191, 2009.
65. Watson B, Bergman SM, Myracle A, Callen DF, Acton RT, Warnock DG. Genetic association of 11beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks. Hypertension 28: 478-482, 1996. (Pubitemid 26296054)
66. Wilson RC, Dave-Sharma S, Wei JQ, Obeyesekere VR, Li K, Ferrari P, Krozowski ZS, Shackleton CH, Bradlow L, Wiens T, New MI. A genetic defect resulting in mild low-renin hypertension. Proc Natl Acad Sci USA 95: 10200-10205, 1998.
67. Wilson RC, Harbison MD, Krozowski ZS, Funder JW, Shackleton CH, Hanauske-Abel HM, Wei JQ, Hertecant J, Moran A, Neiberger RE. Several homozygous mutations in the gene for 11beta-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80: 3145-3150, 1995.
68. Wilson RC, Krozowski ZS, Li K, Obeyesekere VR, Razzaghy-Azar M, Harbison MD, Wei JQ, Shackleton CH, Funder JW, New MI. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80: 2263-2266, 1995.
69. Yue P, Li Z, Moult J. Loss of protein structure stability as a major causative factor in monogenic disease. J Mol Biol 353: 459-473, 2005. (Pubitemid 41356624)